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Abstract 
Background: Chlamydia trachomatis (C. trachomatis) and Mycoplasma genitalium (M. genitalium) are 
considered factors in cervical and ovarian cancer and are associated with flaky cell carcinoma of the cervix. 
The role of steady infection, leading to chronic inflammation, in the of ovarian cancer has received very little 
consideration, although a background of pelvic inflammatory disease (PID) is in a case-control study associate 
to higher risk for ovarian cancer. C. trachomatis, the most common and important cause of PID in the 
developed world is the genital and cervical infectious agent. The aim of this study was prevalence of C. 
trachomatis and M. genitalium in patients with ovarian cancer who referred to Imam Hossein Hospital of 
Shahid Beheshti University of Medical Sciences, Tehran, Iran. 
Materials and Methods: In this descriptive study that was conducted from January 2014 to April 2015, 124 
samples were studied which obtained from patients with ovarian cancer who referred to medical centers of 
Shahid Beheshti University of Medical Sciences. After obtaining samples from ovarian cancer tissue by the 
pathologist, for extraction DNA, samples were transferred to the laboratory of university. To confirm the 
presence of C. trachomatis in samples of ovarian cancer, specific primers for the Major Outer Membrane 
Protein (MOMP) genes of C. trachomais, were designed and used Nested PCR method for detection of M. 
genitalium. Sequencing was performed on the PCR and Nested PCR product to confirm the presence of C. 
trachomatis and M. genitalium. 
Results: Out of 124 samples of ovarian cancer, 62 (50%) samples were malignant cancer and 62 (50%) were 
benign cancer as control group. From 65 malignant samples 14 (22.5%) were Chlamydia trachomatis 
positive. None of the tissue samples of benign cancer of ovary were positive for C. trachomatis. Notably, 
none of the 124 ovarian samples were positive in the M. genitalium standard PCR assay. 
Conclusion: The results suggest that the spread of C. trachomatis in the female with ovarian cancer may be 
common. This finding reflects a possible role of C. trachomatis in the carcinogenesis of ovarian tumors. C. 
trachomatis infection may play a relative role in the pathogenesis of ovarian carcinomas or it could facilitate its 
progression. 
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Ovarian cancer is the most common cancer of 
females and the malignancy with a 15–50% five-year 
survival rate globally1. The pathogenesis of ovarian 
carcinoma, the most lethal of gynecologic 
malignancies with 16-51% globally, is to a great 
extent still unknown. Infections by different 
microbes causing chronic disease have achieved 
increasing interest as possible promoters of various 
carcinomas, and infectious etiologies have been 
established for some carcinoma2.  
Chlamydia trachomatis (Ctr) is the most important 
common microbes of Sexual Transmitted Diseases 
(STD) worldwide, it can be detected from a large 
portion of women with tubal factor infertility (TFI) 
and high anti-Ctr antibodies can be detected in 70% 
of women with tubal occlusion3. Ctr Infection causes 
in man and woman urethral infections, which at 
worst can caused to infertility in the female through 
Fallopian tube injury. Ctr can also infect the eye and 
possible blindness as a result. Chlamydia infections 
count to the causing (STD) worldwide there are 
600,000 reported cases every year. Ctr is the most 
common cause of PID and TFI in the world, and 
infertility is in itself a proposed risk factor for 
ovarian carcinoma4-8. Due to these associations, Ctr 
has been investigated as a common risk factor for 
ovarian cancer by studying Ctr plasma antibodies 
with refusing results. In women with ectopic 
pregnancies, women with TFI, and control women 
Ctr has also been isolate in ovarian tissues. Ctr is co-
infections of the lower genital tract (LGT) play a 
significant role in carcinogenesis of the women upper 
genital tract (UGT), particularly epithelial ovarian 
carcinomas9-11.  
To illustrate the epidemiological associations of 
Chlamydial infections ovarian cancer development it 
has been supposition that the pathogen perhaps 
triggers epigenetic variation in host DNA repair 
pathways or that it changes host cell survival 
pathways by disrupting DNA damage signalling 
pathways associated with tumorigenesis12-15. 
Endocervical epithelial cells are the primary site of 
chlamydial infections. It has been hypothesized which 
the host immune response by Ctr infection is 
responsible for the injury rather than the infection 
itself16-20. 
Mycoplasma genitalium is other one of the important 
microorganisms to develop of genital infection that 
has evolved as an important sexually transmitted 
infectious agent leading PID, possibly with negative 
effects on fertility21,22. M. genitalium was also studied 
as ovarian carcinoma agent was found. The presence 
of Mycoplasma DNA (polymerase chain reaction 
[PCR]) has been found in 59% of patients with ovarian 
cancer.We sought to study and analyze the presence of 
the microorganisms Ctr and M. genitalium in ovarian 
cancer of women with ovarian carcinomas, benign 
conditions cancer and borderline tumors in patients 
with ovarian cancer who refferred to Imam Hossein 
Hospital of Shahid Beheshti University of Medical 
Sciences, Tehran, Iran. 
Methods 
Samples collection: This descriptive study was 
conducted from January 2014 to April 2015. In this 
survey, 62 ovarian cancer (OCa) and 62 non OCa 
pathologycal specimens was collected from patients 
aged between 22-60, referred to Imam Hossein 
hospital, Tehran, Iran from 2004-2014. 
Demographics data including histological type of 
cancer, pathological stage of cancer, OIN (Ovarian 
Intraepithelial Neoplasia), were recorded. Then 
formalin–fixed and paraffin-embedded tissue section 
of open ovarectomy, core niddle biopsy and TURO 
(Trans Urethral Resection of the Oval) samples were 
examined from with OCa and from patients with 
BOH.A single pathologist experienced in urogenital 
pathology performed microscopic evaluation of the 
microscopic slides to determine the cancerous and 
non-cancerous tissue differentiation. The best paraffin-
NBM 19 Novelty in Biomedicine 2016, 1, 18-23 
Prevalence of Chlamydia trachomatis and Mycoplasma genitalium in Patients …                                          Dadashi et al. 
embedded block containing cancerous tissue of the 
patients with ovarian cancer was selected for 
examination.Samples were transported to department 
of Microbiology, Medical School, Shahid Beheshti 
University of Medical Sciences for further analysis. 
DNA extraction: DNA was extracted from formalin-
fixed and paraffin-embedded tissue blocks by G-spin 
TM total DNA extraction Kit (iNtRON 
Biotechnology Co. Korea). First, the paraffin blocks 
were sliced into thin pieces using a sterile razor 
bladder and were placed in a 1.5ml tube (not more 
than 25mg). According to the manufacturer’s 
instruction, xylene was used to removal of paraffin 
and then the bacterial DNA was extracted from tissue 
and measuring of concentration their stored at -20°C. 
Standard PCR: PCR assay for detection of Ctr and 
M. genitalium designed and used specific primers of 
Ctr and M. genitalium PCR detection Kit (Pars Tous 
CO. Iran), respectively. Primers within the Ctr PCR 
mix and M. genitalium PCR Mix were specific for 
conserved 23srRNA and 16srRNA coding region in 
the Ctr and M. genitalium genome respectively. The 
PCR reaction mixture contained 14.6 µl of M. 
genitalium PCR mix, 0.4 µl of HS-Taq DNA 
polymerase and 5 µl of DNA template was used for 
adjusting to a final volume of 20 µl. For negative and 
positive controls and 5 µl of PCR grade water and 5 
µl positive controls, respectively. Nested PCR 
mixture for Ctr and M. genitalium were cycled under 
the following thermal conditions (Table 1 and Table 
2). The PCR products were analyzed on 2% agarose 
gel electrophoresis and the gel was stained with 
ethidium bromide (0.5 µg/ml) and viewed by UV 
transilluminator. The presence of 250 bp and 255 bp 
fragments were positive for Ctr and M. genitalium 
respectively. 
Statistical analysis: Demographics data was 
analyzed using Statistical Package for Social 
Sciences (SPSS) software (version 16). 
Results 
In a total of 124 study patients, there were 62 OCa 
patients and 62 controls with BOH. Study population 
charactistics and GS (grade and stage) information 
are summarized. Ctr was detected in 14 (22.5%) 
samples of 62 OCa patients and there was no Ctr in 
the 62 control with BOH. Notably, none of the 124 
ovarian samples were positive in the M. genitalium 
standard PCR assay. 
The results of PCR: Nested PCR assay for detection 
of C. trachomatis was used. Overall, 22.5% (14%) of 
ovarian cancer samples for the presence of C. 
trachomatis were positive. So that 22.5% (14 cases) of 
cancer samples and 0% of BOH (control group) were 
positive for CT. The results of this study showed that 
in the experimental group (ovarian cancer) and control 
group (BOH) there are positive cases of Chlamydia 
trachomatis [P value <0.001, OR=10.07, 95% CI 
(2.81-36.00)]. Among patients with positive CT 
Location, clinical symptoms, stage of tumor 
progression, tumor type, tumor region in ovarian 
cancer pathological degree, OCP use and age, there 
was no significant relationship (P>0.05). 
 
 
Table 1: Amplification protocol for detection of Ctr. 
Cycle Time Temprature 









1 5Min 72 
 
 Table 2: Amplification protocol for detection of M. genitalium. 
Cycle Time Temprature 









1 3 Min 72 
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Discussion 
The results of this study, indicating the rate of C. 
trachomatis in paraffin blocks ovarian cancer, with a 
prevalence of 22.5% compared with the control 
group (BOH) with a prevalence of 0%. These 
showed that the C. trachomatis is one of the factors 
in the development of ovarian cancer [p value 
<0.001, OR=10.07, 95% CI (2.81-36)]. Mycoplasma 
genitalium, C. trachomatis and papillomavirus are 
known worldwide as a risk factor for cancer of the 
genital area.  
Iran has known as one of the countries that have low 
prevalence of ovarian cancer among world. Recent 
years, it has reported that the rate of ovarian cancer 
from 192,000 in 2005 has increased to 20,000 in 
2008 has increased23. In 2005, 24,498 cases of cancer 
in the female population reported that in 1923 cases 
the cancer related to the ovary (Gynecological) so that 
793 cases are about ovarian cancer that included 
41.2% of all gynecological cancers.  
Ovarian cancer ranked first with 41.2% and cancer of 
endometrium and cervical respectively ranked second 
and third in gynecological cancers24. Ness and his 
colleagues studied in Pennsylvania showed that a 
strong association between Chlamydia species and 
ovarian cancer25. Significant increase in the species C. 
trachomatis infection in cancer tissue has been 
reported in their study.  
In this study, increased IgG against heat shock protein 
of C. trachomatis in patients with ovarian cancer 
suggests that the bacteria associated with ovarian 
cancer. These results confirmed the findings of the 
coming study. In another study by Idahl and 
colleagues in Sweden in 2010, ovarian tissue of 186 
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cases examined for the presence of C. trachomatis, 
Neisseria gonorrhoeae and Mycoplasma genitalium. 
As a result, none of the above organisms were found 
in the ovarian tissue of patients with ovarian cancer 
in other words Idahl and colleagues demonstrated 
that none of the C. trachomatis, Mycoplasma 
genitalium and Neisseria gonorrhoeae bacteria is 
considered as a risk factor for ovarian cancer26, so 
this finding is contrary to the results of the present 
study. The reason for this discrepancy in the results 
of these two studies may be the lack proper isolation 
and low quality and DNA extraction accuracy of 
ovarian biopsy samples in Idahl and colleagues 
research.  
Due to the fact that the prevalence of micro-
organisms in ovarian tissue is relatively low if the 
extraction and isolation of bacterial DNA not be 
accurate and good quality increased the probability 
of bad isolation and therefore a negative test result 
for the presence of studied bacteria. The average age 
of patients with ovarian cancer in the study of Idahl 
and colleagues was 58.9 and by analogy with present 
study 9.7 years increase in age of patients seen. In 
other words, the average age of patients with ovarian 
cancer examined in our study was 49.2 registered. 
This may indicate that ovarian cancer in our study 
was 9.7 years earlier than studied population in 
Sweden. In studies conducted in 1993.1995 and 
2005, C. trachomatis was identified as a common 
cause of having the PID27-29. In another study 
conducted by Haggerty and colleagues in 2008, C. 
trachomatis was isolated from ovarian tissue of 
patients with ectopic pregnancies. The results of this 
study showed that C. trachomatis is associated with 
malignant and genital area disorders30. Another study 
conducted in 2008 by Carvalho JP et al. The results 
of this study suggest that C. trachomatis and 
Mycoplasma genitalium are the most important risk 
factor for chronic inflammation and ultimately Aytla 
ovarian cancer31.  
Conclusion 
Due to the global prevalence of genitourinary 
infections and anatomic location of the ovary, this 
matter that infectious agents may play a role as a risk 
factor for ovarian cancer, it is not surprising. The 
results of this study support the hypothesis of relation 
between sexually transmitted infections and ovarian 
cancer and it can be concluded that the inflammatory 
effects caused by this organism, together with other 
risk factors, can be effective in ovarian cancer. 
Therefore, early diagnosis and early treatment of C. 
trachomatis infections can be used as a common 
method of prevention and treatment of ovarian cancer. 
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